2010
DOI: 10.1016/j.jns.2009.08.025
|View full text |Cite
|
Sign up to set email alerts
|

Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
44
0
1

Year Published

2010
2010
2024
2024

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 59 publications
(45 citation statements)
references
References 126 publications
0
44
0
1
Order By: Relevance
“…In the case of PD, models that reproduce the loss of dopaminergic neurons have demonstrated predictive validity for symptomatic treatments that have changed the lives of patients [6]. However, the same models have not yet proven predictive for neuroprotective treatments [7]. Failed clinical trials of drugs that seemed highly promising when tested in these models have led many investigators to turn to other models in the hope of developing neuroprotective strategies for PD.…”
Section: Introductionmentioning
confidence: 99%
“…In the case of PD, models that reproduce the loss of dopaminergic neurons have demonstrated predictive validity for symptomatic treatments that have changed the lives of patients [6]. However, the same models have not yet proven predictive for neuroprotective treatments [7]. Failed clinical trials of drugs that seemed highly promising when tested in these models have led many investigators to turn to other models in the hope of developing neuroprotective strategies for PD.…”
Section: Introductionmentioning
confidence: 99%
“…Como un potente antioxidante, ácido úrico en el paciente con Parkinson podría sumarse a las defensas contra la enfermedad de un mecanismo que actúa a través del estrés oxidativo. Por otro lado, las relaciones observadas entre la EP y la concentración de urato sistémico pueden reflejar una alteración del metabolismo de purina (especialmente la de adenosina) sobre la base de su interacción con la neurotransmisión de dopamina estriatal (11). Receptores de adenosina están involucrados en la liberación de la modulación de la dopamina estriatal.…”
Section: Parkinsonunclassified
“…Now a days an active search for new cerebro protectors is being carried out among compounds, that affect the compensatory shunt of ATP synthesis in conditions of cerebral ischemia, that modulate glutamate and GABAergic systems, regulate activity of Ca-channels and system of nitrogen oxide and also among antioxidants, neuropeptides, expression inhibitors of proinflammatory cytokines and antagonists of IL-1β-receptors 7 . Thus pharmaceutical approach for novel prevention and treatment strategies of neuro degeneration involves the use of neuroprotective agents in order to delay or stop neuronal cell death or to strengthen cellular defense system, but effective therapies still remain elusive 8 . In view of this, the polyphenolics include, flavonoids, which are found in many herbal extracts, have been shown to be strong ROS scavengers, antioxidants and protectors of neurons from lethal damage in in vitro 9 .…”
Section: Introductionmentioning
confidence: 99%